版本:
中国

BRIEF-Cytrx reports Q1 loss per share $0.10

May 10 Cytrx Corp

* Cytrx reports first quarter 2017 financial results

* Q1 loss per share $0.10

* Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin

* Cytrx Corp- commercial launch of aldoxorubicin is projected for 2018 in U.S

* Cytrx Corp - Cytrx also plans to discuss with European Medicines Agency a path to filing a marketing authorization application. For aldoxorubicin Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐